Bibliografia UJ CM

1/5
Holger N. Lode, Ruth Ladenstein, Sascha Troschke-Meurer, Linda Struppe, Nikolai Siebert, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Evgenia Glogova, Patrick Hundsdoerfer, Angelika Eggert, Anna Zaniewska-Tekieli, Walentyna Balwierz, Aleksandra Wieczorek.
Effect and tolerance of N5 and N6 chemotherapy cycles in combination with dinutuximab beta in relapsed high-risk neuroblastoma patients who failed at least one second-line therapy
Cancers
2023 : Vol. 15, nr 13, il., bibliogr. 39 poz., abstr., sum.
Autor korespondencyjny: Holger N. Lode
Open Access Creative Commons Attribution License CC-BY 4.0.
e-ISSN: 2072-6694
AZ
ORG
AIF
IF: 5.200
Adres url:
Streszczenie w PubMed:
2/5
Tabea Troschke, Aleksandra Wieczorek, Konrad Kulinski, Tomasz Ociepa, Karolina Zielezinska, Holger N. Lode, Tomasz Urasinski.
Pediatric Hematology and Oncology Center integrated by telemedicine : experience, challenges and first results of a cross border network
Healthcare
2023 : Vol. 11, nr 10, il., bibliogr. 15 poz., abstr.
Autor korespondencyjny: Tabea Troschke, Holger N. Lode, Tomasz Urasinski.
Open Access Creative Commons Attribution License CC-BY 4.0
e-ISSN: 2227-9032
AZ
ORG
AIF
IF: 2.800
Adres url:
Streszczenie w PubMed:
3/5
Aleksandra Wieczorek, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, Ruth Ladenstein, Holger N. Lode.
Clinical phenotype and management of severe neurotoxicity observed in patients with neuroblastoma treated with dinutuximab beta in clinical trials.
Cancers
2022 : Vol. 14, nr 8, il., bibliogr. 33 poz., abstr., sum.
Autor korespondencyjny: Holger N. Lode.
Open Access Creative Commons Attribution License CC-BY 4.0.
e-ISSN: 2072-6694
AZ
ORG
AIF
IF: 5.200
Adres url:
Streszczenie w PubMed:
4/5
Ruth Lydia Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Juliet Gray, Roberto Luksch, Walentyna Balwierz, Victoria Castel, Shifra Ash, Maja Beck Popovic, Genevieve Laureys, Godfrey Chi-Fung Chan, Ellen Ruud, Kim Vettenranta, Cormac Owens, Henrik Schroeder, Peter F. Ambros, Sabine Sarnacki, Tom Boterberg, Holger N. Lode.
Risk factors in the HR-NBL-1/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy.
Journal of Clinical Oncology
2020 : Vol. 38, nr 15 suppl., abtr. 10536
2020 ASCO Annual Meeting I.
p-ISSN: 0732-183X
SZZ
SIF
Adres url:
5/5
Lydia Ruth Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Juliet Gray, Roberto Luksch, Walentyna Balwierz, Victoria Castel, Shifra Ash, Maja Beck Popovic, Genevieve Laureys, Godfrey Chi Fung Chan, Ellen Ruud, Kim Vettenranta, Cormac Owens, Henrik Schroeder, Hans Loibner, Peter F. Ambros, Sabine Sarnacki, Tom Boterberg, Holger N. Lode.
Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front-line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.
Journal of Clinical Oncology
2019 : Vol. 37, nr 15, suppl., abstr. 10013
2019 ASCO Annual Meeting I.
p-ISSN: 0732-183X
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ